Team size: 4

What are the key projects that you have been involved in over the past 12 months?

Over the past 12 months, I have driven initiatives that embed compliance as a strategic enabler of innovation, patient access and sustainable business growth. Key projects addressed compulsory payback challenges in the pharmaceutical sector, ensuring legal certainty and business predictability while safeguarding patients’ timely access to innovative therapies and the company’s financial sustainability. We strengthened awareness of the societal value of innovative medicines, highlighting their role in improving health outcomes, supporting economic growth and sustaining healthcare systems.

Internally, we cultivated a compliance mindset across the organisation, demonstrating its impact on decision-making and its direct link to patient care and financial outcomes. Externally, we engaged stakeholders to show that compliance is not a constraint but a catalyst for trust, responsible innovation and long-term financial prosperity.

Through these efforts, legal and compliance functioned not only as a guardian of ethical standards, but also as a driver of tangible value for patients, society and the business.

How can general counsel foster a corporate culture that supports ESG principles and compliance across all levels of the organisation?

In the pharmaceutical industry, compliance is far more than a regulatory obligation; it is the backbone of patient access, innovation and sustainable business growth. Ensuring that patients receive the right treatment at the right time links ethical conduct directly to societal impact and the company’s long-term success.

A General Counsel fosters this culture by being embedded in the business, understanding frontline challenges and translating them into actionable compliance strategies. In this way, compliance becomes a strategic driver that enables innovation, builds trust and delivers measurable value for society, patients and the organisation alike. Engaging internal and external stakeholders — from healthcare professionals to regulators — further reinforces the tangible benefits of compliance, making its value visible and actionable across the ecosystem.

Through strategic presence, cross-functional collaboration and outward-focused engagement, the General Counsel ensures that compliance is not a constraint but a force for patient-centric innovation, business growth and societal benefit.

What is a cause, business or otherwise, that you are passionate about?

I am deeply passionate about advancing healthcare innovation and highlighting its broader societal value. This value extends beyond improved patient outcomes: it means enabling people to live fuller, more productive lives, supporting families and caregivers, alleviating pressure on healthcare systems and contributing to stronger, more resilient economies. Working in the pharmaceutical sector, I have seen how innovative medicines can bring these benefits to life, helping patients not only survive but also continue to participate meaningfully in society.

Strong and growing economies are built on healthy, productive populations. We must therefore recognise that healthcare and innovative medicines represent an investment, not a cost. Evidence clearly shows the link between health and prosperity. Between 2007 and 2017, medicines added an estimated two million healthy years to patients’ lives in the EU, resulting in €27bn in productivity gains and €13bn in avoided healthcare costs. Alternative treatment models, such as subcutaneous formulations, also free valuable clinical time and resources, amplifying benefits for patients and systems alike. Studies consistently confirm that every dollar invested in health can yield two to four dollars in economic return, and in some instances the value created is sufficient to balance, or even exceed, the costs incurred.

We must act now to foster an environment where governments, industry, healthcare professionals and patients work together to secure sustainable access to innovation. By recognising health as wealth, we can unlock a virtuous cycle of better health, economic growth and shared prosperity.